Randomised Trial of Gemcitabine Versus Flec Regimen Given Intra-Arterially for Patients with Unresectable Pancreatic Cancer

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 4 SUPPL., 2003, Pages 51-57

  Cantore, Maurizio ^a,j   Fiorentini, G ^b   Luppi, G ^c   Rosati, G ^d   Caudana, R ^e   Piazza, E ^f   Comella, G ^g   Ceravolo, C ^h   Miserocchi, L ^e   Mambrini, A ^a   Del Freo, A ^a   Zamagni, D ^e   Aitini, E ^e   Marangolo, M ⁱ  

^a USL 1   (Italy)

^b Oncological Department   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d SAN CARLO HOSPITAL   (Italy)

^e CARLO POMA HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h MAGGIORE HOSPITAL   (Italy)

ⁱ SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^j USL n 1 Massa e Carrara   (Italy)

more..

Author keywords

Gemcitabine; Pancreatic cancer

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; CODEINE PHOSPHATE; EPIRUBICIN; FAMOTIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANISETRON; HISTAMINE H2 RECEPTOR ANTAGONIST; MORPHINE; MORPHINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ASTHENIA; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; FEMALE; FEVER; FUNCTIONAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; INOPERABLE CANCER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 12144285980     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Greenlee R.T., Murray T., Bolden S et al: Cancer Statistics, 2000. CA Cancer J Clin 50: 7-33, 2000
2. Burris HA, Moore MJ, Andersen J et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
3. Stomiolo AM, Enas NH, Brown CA, et al: An investigational new drug treatment program for patients with gemcitabine. Results for over 3000 patients with pancreatic carcinoma. Cancer 85: 1261-1268, 1999
4. Cantore M, Pederzoli P, Fiorentini G et al: Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 11: 569-573, 2000
5. Goldstein LJ, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human cancers. J Nat Cancer Inst 1989; 81: 116-124.
6. Miller DW, Fontain M, Kolar C et al: The expression of mutidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 1996; 107: 301-306
7. Verovski VN, Van den Berge DL, Delvaeye MM et al: Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumor PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Br J Cancer 1996; 73: 596-602
8. Kartner N, Riorden JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285-8, 1983
9. Goldstein LJ, Galski H, Fojo A et al: Expression of the multidrug resistance gene product P-glycoprotein in human cancer. J. Natl Cancer Inst. 81: 116, 1989
10. Thiebaut F, Tsuruo T, Hamada H et al: Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissue. PNAS - USA 84: 7735-8, 1987
11. Almoquera C, Shibata D, Forrester K et al: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554, 1988
12. Scarpa A, Capelli P, Mukai K et al: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am. J, Pathol 142: 1534-1543, 1993
13. Chin KV, Ueda K, Pastan I, et al: Modulation of the activity of the promoter of the human MDR1 gene by ras and p53. Science 255: 459-462, 1992
14. Morrow CS, Cowan KH: Glutathione S-transferases and drug resistance. Cancer Cells 2: 15-22, 1990.
15. Klapdor R, Muller C, Seutter R et al: Improvement of survival by efficacy orientated sequential polychemotherapy of exocrine pancreatic cancer. Anticancer Research 20: 5201-5208, 2000